Curasight A/S: Funding, Investors & Team (Sep 2026)
Curasight is a biotech company focused on addressing the need for improved diagnosis and treatment of several cancer indications. The Company has developed a highly specific PET (Positron emission tomography) imaging ligand, uTRACE®, targeting the receptor uPAR, which is a biomarker only expressed in cancer. uTRACE® will become a game-changer in the diagnosis and treatment of cancer patients. In addition, with the promising results obtained within diagnostics Curasight will also pursues uPAR targeted radionuclide therapy using the uTREAT® ligand. As PET imaging and radionuclide therapy is based on the same uPAR binding peptide, a uTRACE® scan can precisely predict where subsequent targeted radiation therapy will be delivered. uTRACE® covers the diagnostic path and uTREAT® covers the therapy. This will be the new management and treatment of cancer patients in the future.
Curasight A/S has raised $7.0M across 2 funding rounds on record, the most recent an undisclosed round of $3.1M announced in Jun 2026.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Curasight A/S Company Profile and Key Stats
Latest funding round on record: Jun 2026.
Curasight A/S Funding Rounds
Curasight A/S raised $3.9M in an undisclosed round announced in Dec 2025.
6 months later, an undisclosed round of $3.1M was announced in Jun 2026.
Curasight A/S Founders and Leadership Team
Contact details for the Curasight A/S team: 1 of 2 have an email address on file.
Start 14-day free trial →Curasight A/S Funding Compared to Other Biotechnology Startups
Curasight A/S' latest round of $3.1M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Curasight A/S in Biotechnology and Copenhagen
Companies Similar to Curasight A/S
Alcolase is a Danish life science start-up that specializes in alcohol flushing.
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on…
ENZIDIA is unleashing the biomanufacturing revolution with an enzyme acceleration revolution
Gefjon Pharma is a biopharmaceutical company focused on developing innovative solutions to combat…
Synuca Therapeutics focused on developing innovative therapies for neurological disorders, particularly…
Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The…
Pioneering new sustainable bio-based ingredients
Muna Therapeutics is a private biopharmaceutical company that discovers and develops therapies that slow or…
EvodiaBio is a company in the bio-industrial sector that develops eco-friendly fragrances for the food and…
Fida Biosystems is a technology that provides the detection and characterization of proteins and…
Chromologics is a company that creates new and original food colorings utilizing natural ingredients. Derived…
WiLD is a networking platform for women in senior positions in business and academia that is motivating and…
Curasight A/S Funding FAQs
What does Curasight A/S do?
Curasight is a biotech company focused on addressing the need for improved diagnosis and treatment of several cancer indications. The Company has developed a highly specific PET (Positron emission tomography) imaging ligand, uTRACE®, targeting the receptor uPAR, which is a biomarker only expressed in cancer. uTRACE® will become a game-changer in the diagnosis and treatment of cancer patients. In addition, with the promising results obtained within diagnostics Curasight will also pursues uPAR targeted radionuclide therapy using the uTREAT® ligand. As PET imaging and radionuclide therapy is based on the same uPAR binding peptide, a uTRACE® scan can precisely predict where subsequent targeted radiation therapy will be delivered. uTRACE® covers the diagnostic path and uTREAT® covers the therapy. This will be the new management and treatment of cancer patients in the future.
How much funding has Curasight A/S raised?
Curasight A/S has raised $7.0M across 2 rounds on record. The most recent is an undisclosed round of $3.1M announced in Jun 2026.
When did Curasight A/S last raise funding?
Curasight A/S' most recent funding round on record is an undisclosed round of $3.1M, announced in Jun 2026.
Who founded Curasight A/S?
FundedIQ lists Andreas Kjaer (Founder), Ulrich Krasilnikoff (Founder) at Curasight A/S.
Where is Curasight A/S headquartered?
Curasight A/S is based in Copenhagen, Hovedstaden, Denmark.
How many employees does Curasight A/S have?
Curasight A/S is in the 1-10 employee band.
How does Curasight A/S' funding compare to other Biotechnology startups?
Curasight A/S' latest round of $3.1M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Curasight A/S Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Curasight A/S is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.